Open AccessConcise Review: Mind the Gap: Challenges in Characterizing and Quantifying Cell‐ and Tissue‐Based Therapies for Clinical Translation
Author(s) -
Rayment Erin A.,
Williams David J.
Publication year - 2010
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.416
Subject(s) - bioprocess , risk analysis (engineering) , biology , biochemical engineering , good manufacturing practice , cell therapy , process (computing) , microbiology and biotechnology , computational biology , bioinformatics , stem cell , computer science , engineering , medicine , paleontology , regulatory affairs , operating system
There are many challenges associated with characterizing and quantifying cells for use in cell‐ and tissue‐based therapies. From a regulatory perspective, these advanced treatments must not only be safe and effective but also be made by high‐quality manufacturing processes that allow for on‐time delivery of viable products. Although sterility assays can be adapted from conventional bioprocessing, cell‐ and tissue‐based therapies require more stringent safety assessments, especially in relation to use of animal products, immune reaction, and potential instability due to extended culture times. Furthermore, cell manufacturers who plan to use human embryonic stem cells in their therapies need to be particularly stringent in their final purification steps, due to the unrestricted growth potential of these cells. This review summarizes the current issues in characterization and quantification for cell‐ and tissue‐based therapies, dividing these challenges into the regulatory themes of safety, potency, and manufacturing quality. It outlines current assays in use, as well as highlights the limits of many of these product release tests. Mode of action is discussed, with particular reference to in vitro surrogate assays that can be used to provide information to correlate with proposed in vivo patient efficacy. Importantly, this review highlights the requirement for basic research to improve current knowledge on the in vivo fate of these treatments; as well as an improved stakeholder negotiation process to identify the measurement requirements that will ensure the manufacture of the best possible cell‐ and tissue‐based therapies within the shortest timeframe for the most patient benefit. S TEM C ELLS 2010;28:996–1004